Advancements in Metastatic Melanoma Treatment

This chapter explores the progression of treatment strategies for metastatic melanoma, contrasting traditional chemotherapy with advancements in targeted therapies and immunotherapies. It highlights key treatment categories, including BRAF-MEK inhibitors and the new combination of Relatlimab and Nivolumab, while discussing the implications of the DreamSeq trial on survival outcomes and treatment sequencing. The chapter also delves into emerging strategies for managing patients with aggressive tumors and the potential benefits of transitional treatment approaches.